IL165809A - Substituted heterocyclic compounds and pharmaceutical compositions containing the same - Google Patents

Substituted heterocyclic compounds and pharmaceutical compositions containing the same

Info

Publication number
IL165809A
IL165809A IL165809A IL16580904A IL165809A IL 165809 A IL165809 A IL 165809A IL 165809 A IL165809 A IL 165809A IL 16580904 A IL16580904 A IL 16580904A IL 165809 A IL165809 A IL 165809A
Authority
IL
Israel
Prior art keywords
compound
mmol
vacuo
inhibitor
etoac
Prior art date
Application number
IL165809A
Other languages
English (en)
Other versions
IL165809A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL165809A0 publication Critical patent/IL165809A0/xx
Publication of IL165809A publication Critical patent/IL165809A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL165809A 2002-07-09 2004-12-16 Substituted heterocyclic compounds and pharmaceutical compositions containing the same IL165809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39455302P 2002-07-09 2002-07-09
PCT/US2003/021331 WO2004004655A2 (en) 2002-07-09 2003-07-08 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (2)

Publication Number Publication Date
IL165809A0 IL165809A0 (en) 2006-01-15
IL165809A true IL165809A (en) 2010-05-17

Family

ID=30115733

Family Applications (1)

Application Number Title Priority Date Filing Date
IL165809A IL165809A (en) 2002-07-09 2004-12-16 Substituted heterocyclic compounds and pharmaceutical compositions containing the same

Country Status (23)

Country Link
US (2) US6875782B2 (enExample)
EP (1) EP1531810B1 (enExample)
JP (1) JP4541883B2 (enExample)
KR (1) KR101120337B1 (enExample)
CN (1) CN1665500A (enExample)
AT (1) ATE543497T1 (enExample)
AU (1) AU2003248861B2 (enExample)
BR (1) BR0312503A (enExample)
CA (1) CA2490972C (enExample)
ES (1) ES2380319T3 (enExample)
GE (1) GEP20084475B (enExample)
HR (1) HRP20050001A2 (enExample)
IL (1) IL165809A (enExample)
IS (1) IS7629A (enExample)
MX (1) MXPA05000279A (enExample)
NO (1) NO329328B1 (enExample)
NZ (1) NZ537251A (enExample)
PL (1) PL375230A1 (enExample)
RS (1) RS20050002A (enExample)
RU (1) RU2325381C2 (enExample)
UA (1) UA79296C2 (enExample)
WO (1) WO2004004655A2 (enExample)
ZA (1) ZA200500029B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537809A (en) * 2002-08-01 2007-05-31 Neurosearch As 1-H-tetrazol-5-yl(phenyl) urea derivative compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
DK1725234T4 (en) * 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
US20060058224A1 (en) * 2004-09-15 2006-03-16 Yancopoulos George D Methods of treating obesity with combination therapeutics
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
JP5140577B2 (ja) * 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
WO2006117743A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
FR2889191A1 (fr) * 2005-07-28 2007-02-02 Cerep Sa Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
PT1942898E (pt) 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007047724A2 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
KR20090012349A (ko) * 2006-05-30 2009-02-03 아스트라제네카 아베 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
AU2007266890B2 (en) * 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103694195B (zh) * 2013-09-18 2016-04-06 华东师范大学 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3290664B2 (ja) 1993-12-28 2002-06-10 明治製菓株式会社 ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
KR100286494B1 (ko) 1995-06-15 2001-04-16 이치로 키타사토 삼환성벤즈아제핀화합물
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) * 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
JPH1067759A (ja) 1996-06-20 1998-03-10 Sankyo Co Ltd 除草性アゾール誘導体
JPH11263775A (ja) 1997-09-08 1999-09-28 Sankyo Co Ltd ヒドロキシアニリン誘導体
IL135303A0 (en) 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
FR2778314B1 (fr) 1998-05-07 2002-06-14 Rhone Poulenc Agrochimie Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ES2215719T3 (es) * 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200514783A (en) * 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CO5261501A1 (es) 1999-11-10 2003-03-31 Takeda Pharmaceutical Derivados de acido pirazol-propionico y sus composiciones farmaceuticas
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2003248861B2 (en) 2009-01-22
BR0312503A (pt) 2007-06-26
NZ537251A (en) 2007-02-23
GEP20084475B (en) 2008-09-10
RU2005103395A (ru) 2005-08-10
ES2380319T3 (es) 2012-05-10
US7507757B2 (en) 2009-03-24
NO329328B1 (no) 2010-09-27
HRP20050001A2 (en) 2005-08-31
KR101120337B1 (ko) 2012-02-29
IL165809A0 (en) 2006-01-15
EP1531810A2 (en) 2005-05-25
PL375230A1 (en) 2005-11-28
NO20045529L (no) 2005-02-03
RU2325381C2 (ru) 2008-05-27
AU2003248861A1 (en) 2004-01-23
CA2490972A1 (en) 2004-01-15
EP1531810B1 (en) 2012-02-01
RS20050002A (sr) 2007-09-21
JP2006501187A (ja) 2006-01-12
US20050119312A1 (en) 2005-06-02
EP1531810A4 (en) 2008-05-28
CN1665500A (zh) 2005-09-07
ATE543497T1 (de) 2012-02-15
WO2004004655A2 (en) 2004-01-15
WO2004004655A3 (en) 2004-10-14
IS7629A (is) 2005-01-05
JP4541883B2 (ja) 2010-09-08
US6875782B2 (en) 2005-04-05
US20040063762A1 (en) 2004-04-01
UA79296C2 (en) 2007-06-11
KR20050025951A (ko) 2005-03-14
MXPA05000279A (es) 2005-03-31
CA2490972C (en) 2012-05-29
ZA200500029B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
EP1531810B1 (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1401433B1 (en) Azole acid derivatives, alone or in combination, for treating diabetes and dyslipidemias; and for treating malignant diseases
US6673815B2 (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7951793B2 (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US6727271B2 (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
RU2327692C2 (ru) Окса- и тиазолпроизводные в качестве антидиабетических агентов и агентов против ожирения
EP2044040A2 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
AU2002310141B2 (en) Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
EP1589006A1 (en) Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees